Xbrane Biopharma AB - ESG Rating & Company Profile powered by AI
If you are employed by Xbrane Biopharma AB and you wish to licence your ESG rating, please contact us. The dashboard contains a Q&A section about Xbrane Biopharma AB. This webpage displays a zero-cost ESG assessment covering Xbrane Biopharma AB.
Xbrane Biopharma AB in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.1; made up of an environmental score of 4.0, social score of 8.0 and governance score of 3.2.
5.1
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 687 | Valbiotis SA | 5.2 | High |
| 687 | Zeria Pharmaceutical Co Ltd | 5.2 | High |
| 724 | Xbrane Biopharma AB | 5.1 | High |
| 724 | Catalyst Pharmaceuticals Inc | 5.1 | High |
| 724 | Adverum Biotechnologies Inc | 5.1 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Xbrane Biopharma AB have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Xbrane Biopharma AB disclose current and historical energy intensity?
Sign up for free to unlockDoes Xbrane Biopharma AB report the average age of the workforce?
Sign up for free to unlockDoes Xbrane Biopharma AB reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Xbrane Biopharma AB disclose its ethnicity pay gap?
Sign up for free to unlockDoes Xbrane Biopharma AB disclose cybersecurity risks?
Sign up for free to unlockDoes Xbrane Biopharma AB offer flexible work?
Sign up for free to unlockDoes Xbrane Biopharma AB have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Xbrane Biopharma AB disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Xbrane Biopharma AB conduct supply chain audits?
Sign up for free to unlockDoes Xbrane Biopharma AB disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Xbrane Biopharma AB conduct 360 degree staff reviews?
Sign up for free to unlockDoes Xbrane Biopharma AB disclose the individual responsible for D&I?
Sign up for free to unlockDoes Xbrane Biopharma AB disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Xbrane Biopharma AB disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Xbrane Biopharma AB disclose water use targets?
Sign up for free to unlockDoes Xbrane Biopharma AB have careers partnerships with academic institutions?
Sign up for free to unlockDid Xbrane Biopharma AB have a product recall in the last two years?
Sign up for free to unlockDoes Xbrane Biopharma AB disclose incidents of discrimination?
Sign up for free to unlockDoes Xbrane Biopharma AB allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Xbrane Biopharma AB issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Xbrane Biopharma AB disclose parental leave metrics?
Sign up for free to unlockDoes Xbrane Biopharma AB disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Xbrane Biopharma AB disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Xbrane Biopharma AB disclose the pay ratio of women to men?
Sign up for free to unlockDoes Xbrane Biopharma AB support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Xbrane Biopharma AB disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Xbrane Biopharma AB reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Xbrane Biopharma AB involved in embryonic stem cell research?
Sign up for free to unlockDoes Xbrane Biopharma AB disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Xbrane Biopharma AB disclose its waste policy?
Sign up for free to unlockDoes Xbrane Biopharma AB report according to TCFD requirements?
Sign up for free to unlockDoes Xbrane Biopharma AB disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Xbrane Biopharma AB disclose energy use targets?
Sign up for free to unlockDoes Xbrane Biopharma AB disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Xbrane Biopharma AB have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Xbrane Biopharma AB
These potential risks are based on the size, segment and geographies of the company.
Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.